NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Deciphera Pharmaceuticals Inc (F: D05)

 
D05 Technical Analysis
5
As on 26th Jun 2025 D05 STOCK Price closed @ 44.42 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 23.38 & Strong Buy for SHORT-TERM with Stoploss of 12.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

D05STOCK Price

Open 44.55 Change Price %
High 44.61 1 Day -0.18 -0.40
Low 44.26 1 Week -0.04 -0.09
Close 44.42 1 Month 2.12 5.01
Volume 4839600 1 Year 33.32 300.18
52 Week High 46.67 | 52 Week Low 10.47
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
4CIA 3.17 2541.67%
 
F Germany Top Losers Stocks
PHO 0.00 -100.00%
PHO 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
 
 
D05
Daily Charts
D05
Intraday Charts
Whats New @
Bazaartrend
D05
Free Analysis
 
D05 Important Levels Intraday
RESISTANCE45.09
RESISTANCE44.88
RESISTANCE44.74
RESISTANCE44.61
SUPPORT44.23
SUPPORT44.10
SUPPORT43.96
SUPPORT43.75
 
D05 Forecast June 2025
4th UP Forecast49.47
3rd UP Forecast47.85
2nd UP Forecast46.85
1st UP Forecast45.85
1st DOWN Forecast42.99
2nd DOWN Forecast41.99
3rd DOWN Forecast40.99
4th DOWN Forecast39.37
 
D05 Weekly Forecast
4th UP Forecast45.06
3rd UP Forecast44.85
2nd UP Forecast44.73
1st UP Forecast44.60
1st DOWN Forecast44.24
2nd DOWN Forecast44.11
3rd DOWN Forecast43.99
4th DOWN Forecast43.78
 
D05 Forecast2025
4th UP Forecast114.76
3rd UP Forecast92.2
2nd UP Forecast78.26
1st UP Forecast64.31
1st DOWN Forecast24.53
2nd DOWN Forecast10.58
3rd DOWN Forecast-3.36
4th DOWN Forecast-25.92
 
 
D05 Other Details
Segment EQ
Market Capital 1694686976.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
D05 Address
D05
 
D05 Latest News
 
Your Comments and Response on Deciphera Pharmaceuticals Inc
 
D05 Business Profile
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Address: 200 Smith Street, Waltham, MA, United States, 02451
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service